NuVision Biotherapies.

Developing high quality and affordable wound care regenerative therapies.

NuVision® Biotherapies Limited is a regenerative medicine company spun out the University of Nottingham in 2015. Dr Andrew Hopkinson founded NuVision on investment from Mercia Fund Management to develop and accelerate to market cutting edge and disruptive regenerative therapies. The MediCity-based manufacturing company produces a ground-breaking high-quality and affordable platform technology, initially focusing on treating front of the eye disease and trauma, but now expanding into the chronic wound arena over the next year.

Technology & Products.

NuVision’s ground-breaking platform technology is Omnigen®, a dehydrated human amniotic membrane-derived regenerative therapy that can be used to treat numerous ophthalmology indications including chemical burns, persistent epithelial defects and dry eye. OmniLenz is the bespoke contact lens that allows simple application of Omnigen to the ocular surfacewithout the need for surgery. This means a regenerative therapy is now routinely available in emergency and ‘in-clinic’ situations where surgery is not immediately accessible or where theatres are unavailable.

The Market.

Omnigen ® is a unique ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. Omnigen will equip those civilian, military and veterinary surgeons tasked with treating damaged corneas with an immediately accessible, consistent high quality, and reliable product.

Fundraising to date.

Since its founding in 2016, NuVision Boitherapies has raised over $3m from investors including University of NOttingham, Biocity, Mercia and MEIF.

Team.

Chair: Dr Mark Treherne
CEO: Dr Andrew Hopkinson

Contact: https://www.nu-vision.co.uk